At 4.4% CAGR, South & Central America Sarcopenia Treatment Market is Projected to be Worth US$ 268.50 Million by 2030, says Business Market Insights

According to Business Market Insights' research, the South & Central America sarcopenia treatment market was valued at US$ 189.59 million in 2022 and is expected to reach US$ 268.50 million by 2030, registering a CAGR of 4.4% from 2022 to 2030. Upsurge in geriatric population and rising awareness about sarcopenia are among the critical factors attributed to drive the South & Central America sarcopenia treatment market growth.

The growing awareness of sarcopenia and its negative impact on health presents a significant scope for advancements in the fields of healthcare and geriatric care. Many advocacy groups and organizations are proactively taking steps to raise the awareness of sarcopenia among the masses. These organizations often work with medical professionals to keep the public updated on the various aspects of certain disorders, such as pathogenicity, target patients, prevention, and treatments, along with underlining the value of prompt diagnosis and treatment. In line with OWH's "Stronger than Sarcopenia" campaign, women are urged to discuss sarcopenia with their healthcare providers, followed by undergoing screen for the illness and taking appropriate therapy if required.

Sarcopenia has been included in the curricula of medical schools and training programs for healthcare professionals such as physicians, nurses, and physical therapists. For example, the OWH worked with Medscape Education to create continuing medical education (CME) credits for healthcare professionals, which will better equip them to detect and treat sarcopenia in their patients. Mainstream media has expanded its coverage of sarcopenia to include articles, news stories, and documentaries. Thus, the elevating awareness regarding sarcopenia is likely to bring new growth trends into the sarcopenia treatment market in the coming years.

On the contrary, unavailability of direct interventions hampers the growth of South & Central America sarcopenia treatment market.

Based on treatment type, the South & Central America sarcopenia treatment market is segmented into vitamin D and calcium supplement, protein supplement, vitamin B12 supplement, and others. The vitamin D and calcium supplement segment held 40.2% share of South & Central America sarcopenia treatment market in 2022, amassing US$ 76.20 million. It is projected to garner US$ 115.44 million by 2030 to register 5.3% CAGR during 2022-2030.

In terms of distribution channel, the South & Central America sarcopenia treatment market is segmented into pharmacies, retail channels, online channels, and others. The pharmacies segment held 40.3% share of South & Central America sarcopenia treatment market in 2022, amassing US$ 76.43 million. It is anticipated to garner US$ 103.52 million by 2030 to expand at 3.9% CAGR during 2022-2030.

Based on country, the South & Central America sarcopenia treatment market is categorized into Brazil, Argentina, and the Rest of South & Central America. Our regional analysis states that Brazil captured 66.5% share of South & Central America sarcopenia treatment market in 2022. It was assessed at US$ 125.98 million in 2022 and is likely to hit US$ 181.86 million by 2030, registering a CAGR of 4.7% during 2022-2030.

Key players operating in the South & Central America sarcopenia treatment market are Abbott Laboratories, Bayer AG, Nestle Health Science SA, Novartis AG, Pfizer Inc, Sanofi SA, Amway Corp, and GSK Plc, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com